CrushSCI.com
97Average days
76Median days
30Fastest days
292Longest days
2082025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

72 days

Long-Term Outcomes of Focal Irreversible Electroporation for Localized Prostate Cancer: Results of a Prospective Pilot Study With Extended Follow-up

Authors
Andrey Morozov; Murad Asali; Igor Matkovskiy; Juan Gomez Rivas; Nirmish Singla; Larisa Tsoy; Evgeniy Fisenko; Leonid Spivak; Konstantin Lokshin; Vadim Rudenko; Denis Chinenov; Eric Barret; Dmitry EnikeevShow moreShow less
Affiliations
Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Urology Department, Barzilai Medical Center, Ben Gurion University of the Negev, Beer Sheva, Israel; Assuta Medical Center, Beer Sheva, Ramat Hyal, Ben Gurion University of the Negev, Beer Sheva, Israel; N.V. Sklifosovsky Institute of Clinical Medicine, Sechenov University, Moscow, Russia; Department of Urology, Hospital Clínico San Carlos, Madrid, Spain; Department of Urology, James Buchanan Brady Urological Institute, The Johns Hopkins University School of Medicine, Baltimore, MD; Institute of Clinical Morphology and Digital Pathology, Sechenov University, Moscow, Russia; Kent and Canterbury Hospital, East Kent Hospitals University Foundation Trust, Canterbury, United Kingdom; Department of Urology, Institut Mutualiste Montsouris, Paris, France; Department of Urology, Rabin Medical Center, Petah Tikva, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Urology, Medical University of Vienna, Vienna, AustriaShow moreShow less
Source PDF DOI Publisher page
292 days

Time to Partial Nephrectomy Versus Cancer-Specific Mortality in 2 to 4 cm Renal Cell Carcinoma

Authors
Maximilian Filzmayer; Michele Nicolazzini; Federico Polverino; Michele Petix; Leonardo Quarta; Filippo Orlandi; Nick J. Lee; Jordan A. Goyal; Nicola Longo; Gennaro Musi; Alberto Briganti; Salvatore Micali; Shahrokh F. Shariat; Marina Kosiba; Clara Humke; Miriam I. Traumann; Fred Saad; Felix K.-H. Chun; Pierre I. KarakiewiczShow moreShow less
Affiliations
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, Canada; Department of Urology, University Hospital, Goethe University Frankfurt, Frankfurt am Main, Germany; Division of Urology, Department of Translational Medicine, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy; Division of Urology, Department of Oncology, University of Turin, Turin, Italy; Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy; Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Urology, Vita-Salute San Raffaele University, Milan, Italy; Department of Urology, AOU di Modena, University of Modena and Reggio Emilia, Modena, Italy; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, United States; Department of Urology, University of Texas Southwestern Medical Center, Dallas, United States; Hourani Center of Applied Scientific Research, Al-Ahliyya Amman University, Amman, JordanShow moreShow less
Source PDF DOI Publisher page
93 days

Rescue Plerixafor-based Mobilization and Outcomes of Salvage High-dose Chemotherapy in Relapsed/Refractory Germ Cell Tumors: A Large Single-center Experience

Authors
Sara Bleve; Maria Concetta Cursano; Cecilia Menna; Caterina Gianni; Giuseppe Schepisi; Valentina Gallà; Chiara Casadei; Serena Mangianti; Stefano Baravelli; Accursio Fabio Augello; Francesco Lanza; Giovanni Rosti; Ismaela Anna Vascotto; Ugo De GiorgiShow moreShow less
Affiliations
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy; Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori,” Meldola, Italy; Cell Processing Laboratory, The Greater Romagna Area Hub Laboratory Pievesestina, Cesena, Italy; Unit of Immunohematology and Transfusion Medicine, Morgagni Pierantoni Hospital, Forlì, Italy; Hematology Unit, Ravenna Hospital, Ravenna, Italy; Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Experimental Medicine, Vito Fazzi Hospital, University of Salento, Lecce, ItalyShow moreShow less
Source PDF DOI Publisher page
69 days

Dual-Tracer 68Ga-PSMA and 68Ga-DOTATATE PET/CT in Advanced Prostate Cancer: Persistent PSMA Expression Despite Clinically Suspected Treatment-Emergent Neuroendocrine Differentiation

Authors
Hiroki Sai; Hidetoshi Kuruma; Atsuya Okada; Yuki Enei; Takafumi Yanagisawa; Chieko Okazaki; Shusuke Akamatsu; Nat Lenzo; Kenta Miki; Takahiro KimuraShow moreShow less
Affiliations
Bashamichi Sakura Clinic, Yokohama City, Japan; Department of Urology, Nagoya University Graduate School of Medicine, Nagoya City, Japan; Jinsenkai MI Clinic, Toyonaka City, Japan; Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; ICON Cancer Centre Theranostics, Perth, Australia; Theranostics Yokohama, Yokohama City, JapanShow moreShow less
Source PDF DOI Publisher page
100 days

Timing of Second-Line Nivolumab and Survival in Metastatic Renal Cell Carcinoma

Authors
Uğur Özberk; Fahriye Tuğba Köş; Perihan Perkin; Öznur Bal; Berkay Yeşilyurt; Mehmet Akif Parlar; Serkan Delen; Bülent YalçınShow moreShow less
Affiliations
Department Of Medical Oncology, Ankara City Hospital, Ankara, Türkiye; Department of Internal Medicine, Ankara City Hospital, Ankara, TürkiyeShow moreShow less
Source PDF DOI Publisher page
79 days

Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study

Authors
Melanie Mayer; Nicholas J. Seewald; Ernesto Ulloa-Pérez; Blanca Homet Moreno; Chethan Ramamurthy; Aram Babcock; Haojie Li; Ronac MamtaniShow moreShow less
Affiliations
Department of Biostatistics, Epidemiology, & Informatics, University of Pennsylvania, Philadelphia, PA; Merck & Co., Inc., Rahway, NJ; Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PAShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Clinical Genitourinary Cancer take to review a manuscript?

As of 2026-11-14, CrushSCI has 15 complete review records for Clinical Genitourinary Cancer. The fastest paper went from submission to acceptance in 30 days (Transient PSA Suppression Without Survival Benefit: Real-World Comparative Effectiveness of Cabazitaxel Plus Carboplatin in Metastatic Castration-Resistant Prostate Cancer (mCRPC), received 2026-06-11, accepted 2026-07-11); the slowest took 292 days. The average is 97 days and the median is 76 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.